"A Pioneering Clinical Trial Investigate if Medical Cannabis Can Treat the Tics in Tourette Syndrome"?

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

The trial is the first of its kind in Australia and will take place at Wesley Medical Research in Brisbane led by Chief Investigator and neuropsychiatrist Dr Philip Mosley. 

Participants will complete two periods of treatment with either a medicinal cannabis drug or a placebo, with both investigators and participants unaware of treatment status until the end of the trial.

Participants in the clinical trial at Wesley Medical Research will complete two six-week "crossover" periods of treatment with active drug or placebo, with both participants and investigators unaware of treatment status until the trial is complete.

"The Antiemetic effect of THC in patients receiving cancer chemotherapy"

Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents.

In a study published in 16 Oct 1975 from 'The New England Journal of Medicine', oral THC (delta-9-tetrahydrocannabinol) was compared with placebo in a controlled, randomized, "double-blind" experiment. 


All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control to determine whether tetrahydrocannabinol had an antiemetic effect. Twenty-two patients entered the study, 20 of whom were evaluable. For all patients an antiemetic effect was observed in 14 of 20 tetrahydrocannabinol courses and in none of 22 placebo courses. 

For patients completing the study, response occurred in 12 of 15 courses of tetrahydrocannabinol and in none of 14 courses of placebo. No patient vomited while experiencing a subjective "high." 

Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducing vomiting caused by chemotherapeutic agents.

"Just realize that this study is from 1975... but still we searching for evidence"

Source: https://www.nejm.org

"Can Medical Marijuana Help Transplant Patients"???

Certain conditions can result in the need for the patient to receive an organ transplant. When you need a transplant, you have to consider your eligibility, existing health issues, and recovery. Since some doctors consider medical marijuana a controversial topic, how does your patient status impact your experience? We can help you understand what to expect as a transplant patient who takes cannabis medicine.

Is Medical Marijuana Safe for Transplant Patients?

When you have an organ transplant, your doctor will give you immunosuppressants. As their name implies, these drugs suppress your immune system to increase your body’s chance of accepting the new organ. Your immune system attacks foreign objects, including organs that don’t belong to your body. If you have regular immune function, it will damage your new organ’s tissue. The immunosuppressants block its ability to attack the new organ so you can keep it in your body.

"Study Discover The Health Effects of Cannabis and Cannabinoids"

In March 2016, the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine (the National Academies) was asked to convene a committee of experts to conduct a comprehensive review of the literature regarding the health effects of using cannabis and/or its constituents that had appeared since the publication of the 1999 IOM report Marijuana and Medicine. 

-The resulting Committee on the Health Effects of Marijuana consisted of 16 experts in the areas of marijuana, addiction, oncology, cardiology, neurodevelopment, respiratory disease, pediatric and adolescent health, immunology, toxicology, preclinical research, epidemiology, systematic review, and public health.


Given the large scientific literature on cannabis, the breadth of the statement of task, and the time constraints of the study, the committee developed an approach that resulted in giving primacy to recently published systematic reviews (since 2011) and high-quality primary research for 11 groups of health endpoints. For each health endpoint, systematic reviews were identified and assessed for quality using published criteria. Only fair- and good-quality reviews were considered by the committee. 

"A Survey of The Attitudes, Beliefs and Knowledge About Medical Cannabis Among Primary Care Providers"

Healthcare providers play a critical role in facilitating patient access to medical cannabis. 
However, previous surveys suggest only a minority of providers believe that medical cannabis confers benefits to patients. 

Significant new knowledge about the potential benefits and harms of medical cannabis has recently emerged. Understanding current attitudes and beliefs of providers may provide 

insight into the ongoing challenges they face as states expand access to medical cannabis.

The survey

This study was funded by the Mayo Clinic and the resercers conducted an electronic survey of primary care providers in a large Minnesota-based healthcare system between January 23 and February 5, 2018 published online in January 22,2019.

They obtained information about providers characteristics,attitudes and beliefs about medical cannabis, the provider comfort level in answering patient questions about medical cannabis, and whether providers were interested in receiving additional education.